Which tumor marker is most commonly elevated in pancreatic ductal adenocarcinoma and is used for surveillance and prognosis?

Explanation

## Tumor Markers in Pancreatic Cancer **Key Point:** CA 19-9 (carbohydrate antigen 19-9) is the most widely used and clinically relevant tumor marker for pancreatic ductal adenocarcinoma, elevated in 80–85% of cases. ### CA 19-9: Clinical Significance **High-Yield:** CA 19-9 is a Lewis antigen-related glycoprotein used for: - **Diagnosis:** Elevated in 80–85% of pancreatic cancer cases - **Prognosis:** Baseline level correlates with tumor burden and stage - **Monitoring:** Serial measurement tracks treatment response and detects recurrence - **Surveillance:** Used in high-risk patients (chronic pancreatitis, familial pancreatic cancer) ### Diagnostic and Prognostic Cutoffs | Clinical Scenario | CA 19-9 Level | Interpretation | | --- | --- | --- | | Normal | <37 U/mL | Baseline | | Borderline elevation | 37–100 U/mL | Requires imaging confirmation | | Significant elevation | >100 U/mL | Highly suggestive of malignancy | | Very high (>1000 U/mL) | >1000 U/mL | Advanced disease, poor prognosis | ### Limitations of CA 19-9 - **Low specificity:** Elevated in benign pancreatitis, cholangitis, cirrhosis, and other malignancies (colorectal, gastric, biliary) - **Lewis antigen dependency:** 10% of population are Lewis antigen-negative and cannot produce CA 19-9 - **Not diagnostic alone:** Must be combined with imaging (CT, MRI, EUS) for diagnosis - **Not suitable for screening:** Poor sensitivity in early-stage disease **Warning:** A normal CA 19-9 does NOT exclude pancreatic cancer, especially in early stages or Lewis antigen-negative patients. ### Comparison with Other Markers | Marker | Pancreatic Cancer Elevation | Primary Use | Notes | | --- | --- | --- | --- | | CA 19-9 | 80–85% | Monitoring, prognosis | Most specific for pancreas | | CEA | 30–50% | Colorectal cancer | Less specific for pancreas | | AFP | Rare | Hepatocellular carcinoma | Not relevant for pancreatic cancer | | PSA | Not elevated | Prostate cancer | Not relevant for pancreatic cancer | **Clinical Pearl:** In a patient with newly diagnosed pancreatic cancer, a baseline CA 19-9 >1000 U/mL indicates advanced, unresectable disease and predicts poor survival even with chemotherapy. [cite:Harrison 21e Ch 297]